Clarametyx Biosciences
Columbus, United States · Biotechnology, Health Care · 9 employees
Clarametyx Biosciences is combating the formidable challenge of chronic respiratory diseases through an innovative technology platform targeting the biofilm—a protective layer around bacteria that drives inflammation and disease exacerbation. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which is in a Phase 2 study for cystic
Funding history
- Funding Round — $27.5M — Jan 2024
- Series series a — $33.0M — Jan 2024
Recent signals
- Apr 02, 2026: Clarametyx Biosciences Promotes Veronica Hall to Chief Development Officer and Brendan Doran to Chief Operating Officer
- Oct 20, 2025: Clarametyx Biosciences Promotes Steve St. Onge to Chief Business Officer
- Jan 07, 2025: Clarametyx Biosciences Awarded Multi-Phased Agreement With CARB-X to Accelerate Anti-Biofilm Vaccine
- Oct 17, 2024: Launched Clarametyx Biosciences Launches Phase 2a Study for Antibody Therapy CMTX-101 Aimed at Treating Cystic Fibrosis Infections
- Apr 22, 2024: Clarametyx Biosciences Appoints Steve St. Onge as Senior Vice President of Corporate Development and Dayna Schwartz as Director of Clinical Development and Portfolio Strategy
- Jan 19, 2024: Raised $27.5M
- Jan 05, 2024: Raised $33.0M in Series series a
See plans & pricing → Track Clarametyx Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.